---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-007253"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:17:32.191408+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ProMIS Q1 net loss $7.3M; completes first cohort enrollment in PRECISE-AD trial

## Summary
- Net loss $7.3M vs $3.6M YoY; R&D expense $5.5M on PMN310 Phase 1b trial costs.
- Cash $8.4M at March 31, 2025, down from $13.3M at Dec 31, 2024.
- First cohort fully enrolled and dosed in PRECISE-AD (Phase 1b) for PMN310 in Alzheimer's.
- Six-month interim results expected 1H 2026; topline data by end of 2026.
- PRECISE-AD designed to detect ARIA with 95% confidence; powered for biomarker changes at 6 months.

## SEC filing metadata
- accession: 0001558370-25-007253
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000155837025007253/0001558370-25-007253-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000155837025007253/pmn-20250512x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-007253
- JSON: https://secwatch.observer/filing/0001558370-25-007253.json
- Plain text: https://secwatch.observer/filing/0001558370-25-007253.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.